Pattern | Orange copy.png
A graphic illustration of a molecular structure with connected orange blobs on a white background.

Connecting the Dots of Market Access

Illustration of an orange molecular structure with three interconnected spheres and a separate sphere below.

125+ Years of Med-Tech Expertise. Five Partners. One Team.

Reimbursement is where promising medical technologies stall or succeed. JD Lymon Group exists to make sure your technology succeeds. We are a specialized market access consulting firm with deep roots in medical technology reimbursement. Our partners have spent decades navigating Medicare and payment policy, payer engagement, and implementing successful reimbursement strategies. 

JD Lymon brings together a deep bench of reimbursement strategists with experience inside both the government and industry. We tailor and craft a reimbursement strategy specific to your technology that integrates with your overall business strategy and path to market. 

Wherever you are on your reimbursement journey, JD Lymon is the partner that turns a complex reimbursement landscape into a clear, executable plan.

Work with us
Two orange molecular structure models with connected spherical nodes.

Why businesses choose The JD Lymon Group

Two large, stylized quotation mark icons, one on each side of the image.

Over the years I have worked for four venture backed startup companies in various stages from early development to mature commercial (e.g.: $100+M in annual sales).  I learned early on in my career that not bringing in Market Access expertise can have catastrophic consequences in your ability to launch and ultimately drive adoption, post approval. 

The team at JD Lymon Group has extensive expertise in all things Market Access and understand the unique needs of each of the phases a startup goes through and appropriately helps teams to plan with an eye on commercial launch.  They are pragmatic in their approaches and bring a wealth of expertise in the categories of evidence requirements, coding strategies, payor and society engagements, such that they have become an invaluable member of our team, even as a consultant.  I can confidently state that their involvement at ShiraTronics, starting in our late development phase and which has carried through our clinical phase, has put us in an excellent position to execute our commercial launch with unique codes and with a well understood strategy related to garnering future payment and coverage. 

I can’t say enough about the value JD Lymon Group brings to our team and would recommend them to any startup or established company that needs expert, up to date, easy to understand consulting assistance as they are “best in class” in what they do!”

Rob Binney, CEO | shiratronics.com

A gloved hand pressing buttons on a touchscreen control panel in a medical or laboratory setting, with a blurred background.
A close-up of a person's upper arm with a medical adhesive patch and round white device attached to the skin.
People in a modern office or conference room attending a presentation about AI assist technology, with multiple monitors and a large screen displaying graphics and text.

A winning combination: We bring together seasoned experts with proven success in health policy, coverage, coding and payment to optimize commercialization strategies.

Orange molecular model with three connected spheres at the top and a horizontal chain of three spheres at the bottom.

JD Lymon Group anticipates the market access challenges our clients face and prepares our clients accordingly. As a result, we have built a sterling reputation for quality and an ability to get results.

At the center of everything we do is collaboration. JD Lymon works closely with its clients to truly understand their business and the pressures placed on those businesses by investors, regulators, the medical community and ultimately, the patients. Based on decades of experience, we provide straightforward, practical strategies designed to meet the real-life demands of this industry. We’ve built a trustworthy reputation by providing practical and actionable market access strategies that help companies overcome the hurdles they face to accelerate their growth.

We care about our clients. Your success
is our success.

Meet the team
Two orange molecular structure models connected by a single line, representing a chemical or molecular diagram.

Our expertise

JD Lymon Group serves medical technology and biopharmaceutical companies at every stage, from founders validating a reimbursement pathway for a prototype to commercial teams optimizing coverage for a product already on the market. 

Our clients include venture-backed startups, growth-stage medical technology companies, and Fortune 500 organizations. What they share is a need for market access expertise that is current, specific and actionable.

Our consulting engagements are built around the full lifecycle of U.S. market access strategy.

A monitor displaying a red heartbeat or ECG line.

Medical Devices

Hospital bed with an IV drip hanging above it.

Durable Medical Equipment (DME)

Computer monitor displaying HTML code with angle brackets and a slash in the center

SaaS and Digital Health Technologies

Illustration of a syringe with an orange tip and needle, viewed at an angle.

Biologics and Orphan Therapies

An abstract orange and black diagram resembling molecular structure or network nodes on a white background.

Consulting Services

  • Reimbursement landscape assessments

    A clear-eyed look at where your technology stands relative to existing coverage, coding, and payment

  • CMS Policy Engagement

    Consistent engagement with CMS on policy issues including MS-DRG and APC reassignment, National Coverage Determinations, and other policy changes

  • Coding application development and submission

    Design and drafting of CPT, ICD-10 and HCPCS applications to support commercialization

  • Incremental Medicare Payment Applications

    Unparalleled expertise across supplemental new technology payment mechanisms, including New Technology Add-On Payment (NTAP), Transitional Pass-Through Payment Status (TPT), New Technology APCs, New Technology Intraocular Lenses, and posterior chamber and anterior chamber intraocular lenses

  • Medical society engagement

    Outreach to specialty physician societies and patient advocacy groups who may impact both coding and coverage decisions

  • Coverage landscape overview

    Review of Medicare and commercial payer policies, payer panel feedback, coding pathways, coverage barriers, and evidence expectations to define the clearest path forward

  • Comprehensive evidence review and generation planning

    Structured review of the clinical literature to identify gaps and strengthen your access story

  • Trial design and analysis

    Prospective input on study design and clinical evidence messaging with active payer medical directors to ensure your evidence meets payer and CMS expectations

  • Clinical trial budget development

    Create template budgets to support clinical trial site budget planning and negotiations

We accelerate market access with strategies that address the Complex Interrelationships among health policy, reimbursement and commercial execution.